News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
721,169 Results
Type
Article (40883)
Company Profile (268)
Press Release (680008)
Multimedia
Podcasts (80)
Webinars (17)
Section
Business (204683)
Career Advice (2022)
Deals (35538)
Drug Delivery (110)
Drug Development (81379)
Employer Resources (173)
FDA (16401)
Job Trends (14942)
News (346383)
Policy (32721)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2565)
Accelerated approval (31)
Adcomms (24)
Allergies (137)
Alliances (49580)
ALS (167)
Alzheimer's disease (1660)
Antibody-drug conjugate (ADC) (305)
Approvals (16666)
Artificial intelligence (500)
Autoimmune disease (143)
Automation (37)
Bankruptcy (362)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (187)
Biotechnology (174)
Bladder cancer (157)
Brain cancer (55)
Breast cancer (631)
Cancer (4750)
Cardiovascular disease (395)
Career advice (1707)
Career pathing (35)
CAR-T (275)
CDC (44)
Celiac Disease (2)
Cell therapy (729)
Cervical cancer (36)
Clinical research (69490)
Collaboration (1666)
Company closure (4)
Compensation (1138)
Complete response letters (52)
COVID-19 (2707)
CRISPR (87)
C-suite (810)
Cystic fibrosis (143)
Data (6144)
Decentralized trials (2)
Denatured (25)
Depression (131)
Diabetes (495)
Diagnostics (6670)
Digital health (44)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (241)
Drug pricing (184)
Drug shortages (28)
Duchenne muscular dystrophy (225)
Earnings (90036)
Editorial (55)
Employer branding (21)
Employer resources (151)
Events (117190)
Executive appointments (958)
FDA (19474)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (23)
Funding (1445)
Gene editing (191)
Generative AI (42)
Gene therapy (581)
GLP-1 (962)
Government (4651)
Grass and pollen (6)
Guidances (383)
Healthcare (18867)
HIV (55)
Huntington's disease (44)
IgA nephropathy (81)
Immunology and inflammation (244)
Immuno-oncology (53)
Indications (103)
Infectious disease (2965)
Inflammatory bowel disease (186)
Inflation Reduction Act (14)
Influenza (110)
Intellectual property (242)
Interviews (315)
IPO (16641)
IRA (49)
Job creations (3642)
Job search strategy (1427)
JPM (56)
Kidney cancer (15)
Labor market (83)
Layoffs (545)
Leadership (30)
Legal (7948)
Liver cancer (91)
Longevity (14)
Lung cancer (638)
Lymphoma (371)
Machine learning (42)
Management (59)
Manufacturing (776)
MASH (161)
Medical device (13755)
Medtech (13807)
Mergers & acquisitions (19952)
Metabolic disorders (1250)
Multiple sclerosis (155)
NASH (16)
Neurodegenerative disease (308)
Neuropsychiatric disorders (86)
Neuroscience (2866)
Neurotech (1)
NextGen: Class of 2026 (6524)
Non-profit (4508)
Now hiring (65)
Obesity (586)
Opinion (256)
Ovarian cancer (164)
Pain (195)
Pancreatic cancer (222)
Parkinson's disease (279)
Partnered (33)
Patents (486)
Patient recruitment (469)
Peanut (55)
People (58812)
Pharmaceutical (63)
Pharmacy benefit managers (29)
Phase 1 (21668)
Phase 2 (30583)
Phase 3 (22788)
Pipeline (5071)
Policy (278)
Postmarket research (2564)
Preclinical (9192)
Press Release (64)
Prostate cancer (234)
Psychedelics (47)
Radiopharmaceuticals (277)
Rare diseases (813)
Real estate (5953)
Recruiting (69)
Regulatory (24409)
Reports (51)
Research institute (2383)
Resumes & cover letters (351)
Rett syndrome (27)
RNA editing (16)
RSV (76)
Schizophrenia (146)
Series A (238)
Series B (184)
Service/supplier (11)
Sickle cell disease (95)
Special edition (21)
Spinal muscular atrophy (157)
Sponsored (41)
Startups (3624)
State (2)
Stomach cancer (17)
Supply chain (104)
Tariffs (84)
The Weekly (53)
Vaccines (983)
Venture capital (86)
Weight loss (376)
Women's health (87)
Worklife (18)
Date
Today (14)
Last 7 days (591)
Last 30 days (2224)
Last 365 days (29793)
2026 (2811)
2025 (30176)
2024 (35218)
2023 (40077)
2022 (51174)
2021 (55715)
2020 (54085)
2019 (46538)
2018 (35021)
2017 (32113)
2016 (31482)
2015 (37555)
2014 (31322)
2013 (26350)
2012 (28576)
2011 (29269)
2010 (27336)
Location
Africa (736)
Alabama (83)
Alaska (7)
Arizona (305)
Arkansas (13)
Asia (39197)
Australia (6404)
California (11154)
Canada (3249)
China (1082)
Colorado (471)
Connecticut (469)
Delaware (332)
Europe (84437)
Florida (1660)
Georgia (353)
Hawaii (3)
Idaho (61)
Illinois (850)
India (62)
Indiana (513)
Iowa (22)
Japan (417)
Kansas (125)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1369)
Massachusetts (7985)
Michigan (319)
Minnesota (621)
Mississippi (5)
Missouri (125)
Montana (31)
Nebraska (28)
Nevada (121)
New Hampshire (78)
New Jersey (2965)
New Mexico (28)
New York (2939)
North Carolina (1434)
North Dakota (8)
Northern California (5435)
Ohio (329)
Oklahoma (21)
Oregon (41)
Pennsylvania (2252)
Puerto Rico (22)
Rhode Island (47)
South America (1107)
South Carolina (65)
South Dakota (1)
Southern California (4340)
Tennessee (172)
Texas (1718)
United States (39531)
Utah (333)
Vermont (1)
Virginia (256)
Washington D.C. (81)
Washington State (913)
West Virginia (4)
Wisconsin (106)
Wyoming (2)
721,169 Results for "bioventures inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
BOOST Pharma Adds Sound Bioventures to Investor Syndicate with SEK 34 Million Investment to Advance Stem Cell Therapy for Osteogenesis Imperfecta
November 3, 2025
·
2 min read
Press Releases
Rapafusyn Pharmaceuticals Closes Over-Subscribed $44 Million Series A Financing to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform
BioTrack Capital and Yonjin Capital join Series A round alongside other investors including 3E Bioventures Capital, Proxima Ventures Ltd., and Lapam Capital Upsized and over-subscribed Series A total funding of $44 million secured Rapafusyn’s RapaGlue™ platform rapidly discovers non-degrading molecular glues, a validated and highly sought-after modality to address challenging disease targets
September 4, 2025
·
1 min read
Sound Bioventures joins £19M ($24.5M) financing in UK oncolytic virus company Theolytics
Sound Bioventures announced a new investment in Theolytics, a UK biotechnology company developing next-generation oncolytic viral therapies.
April 17, 2024
·
4 min read
Press Releases
Capital BioVentures Announces Inaugural Cohort for Ottawa Biotech Accelerator Program
December 3, 2024
·
6 min read
BioMidwest
NephroDI Therapeutics Announces Investment by Sound Bioventures to Accelerate Development of NDI-5001 as a Potential First-in-Class Therapy for Pediatric Orphan Kidney Disease
NephroDI Therapeutics (NephroDI), a near-clinical stage pharmaceutical company focusing on kidney disorders, announces a Series A investment from life sciences VC Sound Bioventures.
June 20, 2024
·
4 min read
Pharm Country
Harmonic Discovery Announces Licensing Agreement with BioVentures and UCSF for FLT3 Mutated AML Development Program
Harmonic Discovery announced an exclusive licensing agreement of a novel small-molecule drug candidate for the treatment of FLT3 mutated acute myeloid leukemia from BioVentures and UC San Francisco.
January 30, 2024
·
3 min read
Theolytics successfully closes latest financing raising total of £19M ($24.5M) and welcomes Sound Bioventures as new investor
Theolytics, a biotechnology company developing next-generation oncolytic viral therapies, announced it has successfully closed its latest financing round, raising a total of £19M with the addition of Sound Bioventures as a new investor.
April 17, 2024
·
4 min read
Press Releases
Repare Announces Completion of Acquisition by XenoTherapeutics, Inc.
January 29, 2026
·
6 min read
Press Releases
Encision Inc. Announces Fiscal 2026 Third Quarter Results
February 4, 2026
·
1 min read
Press Releases
Therma Bright Inc. Investee Company, InStatin Expands its Inhaled Statin Programs to include COPD (Chronic Obstructive Pulmonary Disease) as its Lead Indication.
Includes Asthma in its strategic plans and Strengthens its Team in 2024-2025
December 18, 2025
·
5 min read
1 of 72,117
Next
